ロード中...
Sticking it to KRAS: Covalent Inhibitors Enter the Clinic
Drugs that target KRAS 12C covalently, AMG 510 and MRTX849, are now in the clinic. Recent papers describe development of these compounds, their selectivity and properties, early clinical data, and potential combination therapies. These papers herald a new era in Ras research, with improved drugs and...
保存先:
| 出版年: | Cancer Cell |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7891852/ https://ncbi.nlm.nih.gov/pubmed/31951561 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2019.12.009 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|